Glatiramer Acetate-associated Refractory Immune Thrombocytopenic Purpura
  • Iftach Sagy
    Department of Medicine F, Soroka University Medical Center, Beer-Sheva Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva
  • Leah Shalev
    Department of Medicine F, Soroka University Medical Center, Beer-Sheva Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva
  • Itai Levi
    Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva Department of Hematology, a University Medical Center, Beer-Sheva
  • Elena Shleyfer
    Department of Medicine F, Soroka University Medical Center, Beer-Sheva Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva
  • Svetlana Valdman
    Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva Department of Hematology, a University Medical Center, Beer-Sheva
  • Leonid Barski
    Department of Medicine F, Soroka University Medical Center, Beer-Sheva Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva

Keywords

Glatiramer acetate, drug associated immune thrombocytopenic purpura, thrombocytopenia.

Abstract

We present a case of glatiramer acetate-associated refractory immune thrombocytopenic purpura (ITP) in a female patient with multiple sclerosis. A search of MEDLINE/PubMed did not find any connection between glatiramer acetate and thrombocytopenia, specifically ITP. The autoimmune reaction was resistant to conservative ITP treatment, and was eventually managed only by splenectomy. To the best of our knowledge, this is the first report of glatiramer acetate-associated ITP. Physicians should be aware of this condition, and consider performing routine blood counts at the beginning of glatiramer acetate treatment.

VIEW THE ENTIRE ARTICLE

References

  • Galetta SL, Markowitz C. US FDA-approved disease-modifying treatments for multiple sclerosis. CNS Drugs 2005;19:239-252.
  • Johnson K, Brooks B, Cohen J, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276.
  • Neunert C, Lim W, Crowther M, Cohen A, Solberg Jr L, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-4207.
  • van den Bemt PMLA, Meyboom RH, Egberts AC. Drug-induced immune thrombocytopenia. Drug Safety 2004;27:1243-1252.
  • George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998;129:886-890.

    • Views: 1462
    HTML downloads: 345
    PDF downloads: 370

    Published: 2016-04-12
    Issue: Vol. 3 No. 3 (view)

    How to cite:
    1.
    Sagy I, Shalev L, Levi I, Shleyfer E, Valdman S, Barski L. Glatiramer Acetate-associated Refractory Immune Thrombocytopenic Purpura. EJCRIM 2016;3 doi:10.12890/2016_000399.